IN2015KN00329A - - Google Patents
Info
- Publication number
- IN2015KN00329A IN2015KN00329A IN329KON2015A IN2015KN00329A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A IN 329KON2015 A IN329KON2015 A IN 329KON2015A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A
- Authority
- IN
- India
- Prior art keywords
- compositions
- diseases
- disclosed
- methods
- encompass
- Prior art date
Links
- 102000004388 Interleukin-4 Human genes 0.000 abstract 5
- 108090000978 Interleukin-4 Proteins 0.000 abstract 5
- 229940028885 interleukin-4 Drugs 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681490P | 2012-08-09 | 2012-08-09 | |
| US201261725791P | 2012-11-13 | 2012-11-13 | |
| US201361825980P | 2013-05-21 | 2013-05-21 | |
| PCT/US2013/054164 WO2014074186A2 (en) | 2012-08-09 | 2013-08-08 | Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00329A true IN2015KN00329A (pl) | 2015-07-10 |
Family
ID=50685291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN329KON2015 IN2015KN00329A (pl) | 2012-08-09 | 2013-08-08 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9738696B2 (pl) |
| EP (1) | EP2882449B1 (pl) |
| JP (2) | JP6445434B2 (pl) |
| CN (2) | CN104619334A (pl) |
| IN (1) | IN2015KN00329A (pl) |
| WO (1) | WO2014074186A2 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018064574A1 (en) * | 2016-09-30 | 2018-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Variant type iii interferons and synthekines |
| JP2018157812A (ja) * | 2017-03-23 | 2018-10-11 | 東ソー株式会社 | 試料中に含まれる細胞の検出方法 |
| WO2018182935A1 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Synthekine compositions and methods of use |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019232523A1 (en) | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2022032045A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL10Rα/IL2Rγ SYNTHETIC CYTOKINES |
| EP4532018A4 (en) * | 2022-05-24 | 2026-04-22 | Univ Pittsburgh Commonwealth Sys Higher Education | EYE COMPOUNDS BASED ON INTERLEUKIN 4 AND/OR INTERLEUKIN 13 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656947A1 (en) | 1992-08-21 | 1995-06-14 | Schering Corporation | Human interleukin-13 |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
| FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| US6335426B1 (en) | 1996-06-14 | 2002-01-01 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US6028176A (en) * | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| US6673602B1 (en) | 1999-06-11 | 2004-01-06 | The General Hospital Corporation | Herpes simplex virus amplicon vector targeting system and method of using same |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| CA2388562C (en) | 1999-09-09 | 2014-07-22 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| AU7863900A (en) | 1999-10-06 | 2001-05-10 | Penn State Research Foundation, The | Il13 mutants |
| CA2404763A1 (en) | 1999-11-11 | 2001-05-17 | Raj K. Puri | Mutated il-13 molecules and their uses |
| GB0004016D0 (en) | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| DE60142479D1 (de) | 2000-08-30 | 2010-08-12 | Penn State Res Found | Aminosäureaustauschmutanten von interleukin 13 |
| AU2002224408B2 (en) | 2000-10-18 | 2007-08-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| MXPA03011158A (es) | 2001-06-07 | 2004-02-27 | Wyeth Corp | Estructura de solucion de il - 13 y sus usos. |
| US20040248260A1 (en) | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| CA2593648A1 (en) | 2005-01-10 | 2006-07-13 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
| US20100317577A1 (en) | 2005-09-09 | 2010-12-16 | Department Of Health And Human Services | Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation |
| US20070160658A1 (en) | 2005-10-20 | 2007-07-12 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| WO2007146046A2 (en) | 2006-06-07 | 2007-12-21 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| WO2008101671A2 (en) | 2007-02-19 | 2008-08-28 | Apogenix Gmbh | Il-4 fc fusion proteins |
| EP2197909A4 (en) | 2007-08-24 | 2014-12-03 | Univ Minnesota | REAGENTS ON RECIPES |
| CN102112144A (zh) | 2008-05-16 | 2011-06-29 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
| WO2010031185A1 (en) | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| US20100183545A1 (en) | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| JP2010154842A (ja) | 2008-12-03 | 2010-07-15 | Koji Kawakami | Ｅｇｆｒを標的にした新規抗がんキメラペプチド |
| US20110023680A1 (en) | 2009-07-30 | 2011-02-03 | Kuo-Chung Wang | Pcb cutter module with detachable cutters |
| TWI397428B (zh) | 2009-12-29 | 2013-06-01 | 財團法人工業技術研究院 | 標的第四介白素受體之傳輸系統 |
| WO2011106779A1 (en) | 2010-02-26 | 2011-09-01 | Aerovance Inc. | Use of modified il-4 mutien receptor antagonists to treat dermatitis |
| JP5734951B2 (ja) | 2010-03-03 | 2015-06-17 | シャープ株式会社 | 表示装置およびその駆動方法、ならびに液晶表示装置 |
| WO2012054929A2 (en) | 2010-10-22 | 2012-04-26 | Protox Therapeutics Corp. | Use of human serum albumin to decrease antigenicity of therapeutic proteins |
| US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
| CN107164330A (zh) | 2011-04-08 | 2017-09-15 | 贝勒医学院 | 使用嵌合细胞因子受体逆转肿瘤微环境的影响 |
| WO2012139112A1 (en) | 2011-04-08 | 2012-10-11 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins |
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| WO2015042705A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Biopharma Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| WO2015070210A1 (en) | 2013-11-11 | 2015-05-14 | Wake Forest University Health Sciences | Epha3 and multi-valent targeting of tumors |
| CN106459990B (zh) | 2014-02-07 | 2021-06-01 | 麦克马斯特大学 | 三功能t细胞抗原偶联物及其制备方法和用途 |
| US20180133252A9 (en) | 2014-09-09 | 2018-05-17 | Unum Therapeutics Inc. | Chimeric receptors and uses thereof in immune therapy |
| CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| SG10202103475XA (en) | 2014-12-02 | 2021-05-28 | Prospect Chartercare Rwmc Llc | Methods and compositons for treating cancer |
| CN116003593A (zh) | 2016-01-11 | 2023-04-25 | 苏黎世大学 | 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白 |
| WO2018112266A1 (en) | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| WO2019051204A1 (en) | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| US20220347268A1 (en) | 2019-02-07 | 2022-11-03 | Medicenna Therapeutics, Inc. | Il-4r as a biomarker in cancer |
| CN116390744A (zh) | 2020-06-24 | 2023-07-04 | 梅迪塞纳医疗股份有限公司 | 双功能性超级因子及其用途 |
-
2013
- 2013-08-08 IN IN329KON2015 patent/IN2015KN00329A/en unknown
- 2013-08-08 US US14/419,873 patent/US9738696B2/en active Active
- 2013-08-08 WO PCT/US2013/054164 patent/WO2014074186A2/en not_active Ceased
- 2013-08-08 CN CN201380047839.4A patent/CN104619334A/zh active Pending
- 2013-08-08 JP JP2015526711A patent/JP6445434B2/ja active Active
- 2013-08-08 CN CN201910717548.0A patent/CN110615835A/zh active Pending
- 2013-08-08 EP EP13852778.3A patent/EP2882449B1/en active Active
-
2017
- 2017-07-27 US US15/662,180 patent/US10738096B2/en active Active
-
2018
- 2018-06-22 JP JP2018118931A patent/JP2018161143A/ja active Pending
-
2020
- 2020-08-07 US US16/988,460 patent/US12187771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2882449A2 (en) | 2015-06-17 |
| JP2015525574A (ja) | 2015-09-07 |
| JP2018161143A (ja) | 2018-10-18 |
| US9738696B2 (en) | 2017-08-22 |
| JP6445434B2 (ja) | 2018-12-26 |
| WO2014074186A3 (en) | 2014-06-19 |
| WO2014074186A2 (en) | 2014-05-15 |
| US10738096B2 (en) | 2020-08-11 |
| CN104619334A (zh) | 2015-05-13 |
| US20160244499A1 (en) | 2016-08-25 |
| US12187771B2 (en) | 2025-01-07 |
| CN110615835A (zh) | 2019-12-27 |
| US20210188932A1 (en) | 2021-06-24 |
| US20180016316A1 (en) | 2018-01-18 |
| EP2882449B1 (en) | 2019-05-15 |
| EP2882449A4 (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00329A (pl) | ||
| CY1123106T1 (el) | Αγωγη ανοσοσχετιζομενων και φλεγμονωδων νοσων | |
| MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
| PH12013502671A1 (en) | Glucagon/glp-1 receptor co-agonists | |
| MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| MX2015001871A (es) | Celulas asesinas naturales y usos de las mismas. | |
| MY189483A (en) | Purinone derivative | |
| MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
| UY34617A (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas | |
| AU355788S (en) | Portable activity monitor | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| MX2015014438A (es) | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. | |
| MX384095B (es) | Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad. | |
| MX375592B (es) | Composiciones y su uso para tratar hemoglobinopatias. | |
| MY156697A (en) | Modified tuberculosis antigens | |
| CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| EP2558124A4 (en) | POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION | |
| CA142107S (en) | Log splitting wedge | |
| MX2016006688A (es) | Inhibidores tetraciclicos de autotaxina. | |
| MX2015003765A (es) | Arterivirus. | |
| EP2955776A4 (en) | OXYGEN REDUCTION CATALYST, OXYGEN REDUCTION ELECTRODE AND FUEL CELL | |
| ES2673028T3 (es) | Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas | |
| CO6700840A2 (es) | Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia | |
| MY175743A (en) | Combination treatment comprising sulphated glycosaminoglycans for inducing labor |